Navigation Links
FDA Approves Horizant To Treat Restless Legs Syndrome
Date:4/7/2011

SILVER SPRING, Md., April 7, 2011 /PRNewswire-USNewswire/ -- On April 6, the U.S. Food and Drug Administration approved Horizant Extended Release Tablets (gabapentin enacarbil), a once-daily treatment for moderate-to-severe restless legs syndrome (RLS).

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

RLS is a disorder that causes a strong urge to move the legs. This urge often occurs with unpleasant feelings in the legs. People who have RLS describe feeling pulling, itching, tingling, burning, or aching in their legs, and moving the legs temporarily relieves these feelings. The urge to move often happens when a person is inactive, and the symptoms typically are worse in the evening and early morning.

"People with restless legs syndrome can experience considerable distress from their symptoms," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Horizant provides significant help in treating these symptoms."  

The effectiveness of Horizant was studied in two 12-week clinical trials in adults. The trials showed that people taking the medication had an improvement in their RLS symptoms, compared with people taking an inactive pill (placebo).

Horizant will be dispensed with an FDA-approved Medication Guide that explains the drug's uses and risks. Horizant may cause drowsiness and dizziness and can impair a person's ability to drive or operate complex machinery.

Horizant contains gabapentin enacarbil that becomes gabapentin, a drug used to treat seizures in people with epilepsy, when absorbed into the body. All drugs used to treat epilepsy carry warnings that they may cause suicidal thoughts and actions in a small number of people. Horizant will have the same warning.

Horizant was developed by GlaxoSmithKline of Research Triangle Park, N.C., and Xenoport of Santa Clara, Calif.

For information:

National Institute of Neurological Disorders and Stroke: Restless Legs Syndrome Information Page
http://www.ninds.nih.gov/disorders/restless_legs/restless_legs.htm

Approved Drugs: Questions and Answers
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm      

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves New Treatment for Rare Form of Thyroid Cancer
2. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
3. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
4. FDA Approves New Treatment for a Type of Late-Stage Skin Cancer
5. FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age
6. FDA Approves Gadavist for Central Nervous System Scans
7. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
8. FDA Approves Device to Maintain Blood Flow During Artery Bypass Brain Surgery
9. FDA Approves BENLYSTA® for Lupus in Breakthrough for Millions of Sufferers
10. FDA Approves Revised Alphanate® Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
11. UPDATE: FDA Approves New Drug to Treat Chronic Obstructive Pulmonary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... Lilly and Company (NYSE: LLY ) has entered ... patent litigation in the U.S. District Court for the Eastern ... ® (tadalafil) unit dose patent. This patent was previously ... the agreement, Cialis exclusivity is now expected to end at ... dose patent for Cialis is valid and infringed by companies ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
(Date:7/10/2017)... -- The tenth annual BioPharm America™ will take ... the Sheraton Boston Hotel, September 26–27. The event will ... makers and innovative biotech startup companies. The event is ... impactful days. BioPharm America is now part of Biotech ... with 4,500+ life science industry influencers participating in 8+ ...
Breaking Medicine Technology:
(Date:7/23/2017)... ... July 23, 2017 , ... “I Am Not Nothin’: The Serpent Handler’s Daughter” ... barely read and write and a brokenhearted young soldier who turned to whiskey after ... novel about the power of simple faith is the work of published author Tommy ...
(Date:7/23/2017)... ... 23, 2017 , ... Viora Ltd., a leading medical aesthetics ... 9,038,640 by the United States Patent and Trademark Office. The patent applies to ... Vacuum, and Cooling mechanisms to further increase the efficacy and safety of final ...
(Date:7/22/2017)... ... July 22, 2017 , ... The arthroscopic superior capsule ... opportunity to return to sports and jobs that require heavy physical work, as ... Annual Meeting in Toronto, Ontario, Canada. , “We studied 100 patients ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... assistance and financial consultations to communities in the greater Denver region, is announcing ... recently diagnosed with a very rare kind of epilepsy. , Until a few ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... planning services to communities in the greater Birmingham area, is joining the Chris ... underprivileged young people in the region. , The Chris Hammond Youth Foundation maintains ...
Breaking Medicine News(10 mins):